Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMGN $7.63 1.4300 +23.06%
CBMG $16.98 1.1600 +7.33%
CNDO $2.50 0.1500 +6.38%
ARGS $8.32 0.3400 +4.26%
STML $15.48 0.4900 +3.27%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

EPZM $19.14 -1.4000 -6.82%
GALT $3.22 -0.2300 -6.67%
SRNE $10.09 -0.6900 -6.40%
TGTX $14.24 -0.9100 -6.01%
VSTM $7.30 -0.4100 -5.32%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Drugs’ Path to China Slows as Regulatory Delays Add Up, J&J Says

(Bloomberg) Jan 21, 2015 - The Chinese pharmaceutical market is becoming increasingly challenging for drug companies because of how long regulators there take to approve new medicines, Johnson & Johnson’s Chief Scientific Officer Paul Stoffels said.
read article 

Counterfeit Cialis Found Entering U.S. By Mail: FDA

(Reuters) Jan 21, 2015 - The U.S. Food and Drug Administration said counterfeit versions of the erectile dysfunction drug Cialis were found in the mail en route to a customer in the United States, and it is alerting consumers and doctors to be on the lookout for fakes.
read article 

Docs Urge Big Changes to Health Records Program

(The Hill) Jan 21, 2015 - A coalition of 35 medical societies is urging federal regulators to make major changes to the Meaningful Use electronic health records (EHR) program.
read article 

Predictable Fault Lines Emerge as Perennial Doc-Fix Debate Begins

(Modern Healthcare) Jan 21, 2015 - There's only one outstanding issue left to resolve before Congress can pass a permanent “doc fix”: how to cover the roughly $140 billion price tag.
read article 

1,700 Hospitals Win Quality Bonuses From Medicare, But Most Will Never Collect

(Kaiser Health News) Jan 22, 2015 - Medicare is giving bonuses to a majority of hospitals that it graded on quality, but many of those rewards will be wiped out by penalties the government has issued for other shortcomings, federal data show.
read article 

Curis, Aurigene Partner to Develop Precision Oncology Targets

(Pharmaceutical Business Review) Jan 22, 2015 - Curis and Aurigene Discovery Technologies have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets.
read article 

Kite Pharma Announces Expanded Agreement With Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches For Cancer Immunotherapy

(CNBC) Jan 22, 2015 - Kite Pharma, Inc today announced that the Company has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR T-cell therapy, the technology underlying Kite's most advanced programs in cancer immunotherapy.
read article 

UK Start-Up Autolus Enters CAR-T Cancer Race

(PharmaTimes [UK]) Jan 22, 2015 - Backed with £30 million from healthcare investment group Syncona and following major support from the UK government, University College London has created Autolus to develop CAR T-cell products to fight cancer.
read article 

Ventana Seeks FDA Premarket Approval for Lung Cancer CDx

(GenomeWeb) Jan 21, 2015 - Ventana Medical Systems, a Roche business, today announced it has submitted the ALK (D5F3) CDx Assay to the US Food and Drug Administration for premarket approval.
read article (free registration required) 

Celgene, Biotech's Ace Dealmaker, Bets on Canada's Zymeworks

(Forbes) Jan 21, 2015 - Celgene, the big maker of blood cancer drugs, has gained a reputation for anointing biotech startups before they break out. Now it’s betting on a little Canadian biotech, Zymeworks, with technology for engineering new types of targeted antibody drugs.
read article 

ASCO: 'High-Risk' Project 'Must Be Done'

(Medscape Medical News) Jan 22, 2015 - The organization has been claiming that CancerLinQ will revolutionize cancer care for months. Now they have a technology partner to help them.
read article (free registration required) 

Immunomedics Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Gastrointestinal Cancers

(Immunomedics) Jan 20, 2015 - Immunomedics, Inc., today announced that sacituzumab govitecan, the Company’s lead investigational antibody-drug conjugate (ADC), produces partial response (PR) in some patients with metastatic esophageal and colorectal cancers who had been heavily pretreated.
read corporate press release 

Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compared to Bicalutamide in Metastatic Prostate Cancer

(MarketWatch) Jan 22, 2015 - Medivation, Inc. and Astellas Pharma Inc. today announced topline results from the Phase 2 TERRAIN trial comparing enzalutamide with bicalutamide in men with metastatic castration-resistant prostate cancer.
read article 

CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma

(Yahoo! Finance) Jan 22, 2015 – Aldoxorubicin demonstrates 2-fold increase in likelihood of surviving more than 2 years versus doxorubicin and 27% reduction in the risk of death.
read article 

Major Study Links Gene to Drug Resistance in Testicular Cancer

(ICR [UK]) Jan 22, 2015 - A major research study has uncovered several new genetic mutations that could drive testicular cancer – and also identified a gene which may contribute to tumours becoming resistant to current treatments.
read press release 

New Cancer-Fighting Strategy Would Harden Cells to Prevent Metastasis

(Johns Hopkins Medicine) Jan 21, 2015 - Existing cancer therapies are geared toward massacring tumor cells, but Johns Hopkins researchers propose a different strategy: subtly hardening cancer cells to prevent them from invading new areas of the body.
read press release 

Close Monitoring of Renal Tumors May Provide Alternative to Surgery

(Mount Sinai Hospital) Jan 21, 2015 - In patients with small renal tumors confined to the kidneys, close, active monitoring, as opposed to immediate surgery, is associated with low rates of tumor growth or death, according to a research study.
read press release 

Palbociclib For Breast Cancer Inches Toward FDA Approval

(Medscape Medical News) Jan 21, 2015 - Palbociclib, the first CDK 4/6 inhibitor, has shown a doubling of progression-free survival in postmenopausal women with ER-positive, HER2-negative advanced-stage breast cancer.
read article (free registration required) 

Use of 'the Pill' Tied to Higher Risk For Rare Brain Cancer

(Philadelphia Inquirer/HealthDay News) Jan 22, 2015 - The risk for developing a rare form of brain cancer known as glioma appears to go up with long-term use of hormonal contraceptives such as the Pill, new Danish research suggests.
read article 

Lab Tests Imply Formaldehyde Risk in Some E-Cigarette Vapor

(ABC News/Associated Press) Jan 21, 2015 - Using certain electronic cigarettes at high temperature settings could potentially release more formaldehyde, a cancer-causing chemical, than smoking traditional cigarettes does, new lab tests suggest.
read article 

E-Cigarettes Can Churn Out High Levels Of Formaldehyde

(NPR/Shots blog) Jan 21, 2015 - Vapor produced by electronic cigarettes can contain a surprisingly high concentration of formaldehyde — a known carcinogen — researchers reported Wednesday.
read article 

Taking Contraceptive Pill for Five Years Doubles Risk of Brain Tumour, Warn Scientists

(The Telegraph [UK]) Jan 22, 2015 - Taking the pill for at least five years more than doubles the risk of developing a brain tumour, a study has shown.
read article 

Merck Will No Longer Sell its Victrelis Hepatitis C Drug in the U.S.

(Wall Street Journal/Pharmalot blog) Jan 21, 2015 - Rival hepatitis C drugs from Merck and Vertex Pharmaceuticals made a big splash when they debuted in 2011, marking an advance in treatment of the liver disease and a lucrative new market segment.
read article (paid subscription required) 

Bristol-Myers Squibb Names Giovanni Caforio CEO

(NASDAQ/ Jan 20, 2015 - Giovanni Caforio will become chief executive officer, while Lamberto Andreotti will become executive chairman of board on May 5.
read article 

Novartis Wins U.S. Approval for First of New Psoriasis Drugs

(BloombergBusinessweek) Jan 21, 2015 - Novartis AG won U.S. approval for the first in a new line of psoriasis drugs that aim to better treat the itchy, sometimes debilitating skin condition.
read article